An example is zanidatamab, a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2 (i.e., the trastuzumab binding domain and the pertuzumab binding domain) that is currently under investigation for early stage and metastatic HER2-positive BC (NCT05035836, NCT04224272, NCT02892123). This evidence concerns the gene ERBB2 and breast cancer.